India plans to squeeze more from both patented drugs and generics
This article was originally published in Scrip
Executive Summary
India is sending a clear message to drug-makers that it needs value-for-money from pharmaceuticals with two policy initiatives that aim directly to cut drug prices. One concerns a pricing system for patented medicines, while the other looks to expand the distribution of cut-price unbranded generic medicines around five-fold by the end of 2012, and 25-fold by the end of 2017.